Pharmacogenomics: The Promising Future of Clinical Therapeutics

被引:0
|
作者
Arafah, Azher [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
关键词
pharmacogenetics; pharmacogenomics; adverse drug reaction; drug transporters; gene variants; precision medicine; IMPLEMENTATION CONSORTIUM GUIDELINES; DRUG-METABOLIZING-ENZYMES; PERSONALIZED MEDICINE; BREAST-CANCER; GENETIC-CONTROL; CYP2C19; GENOTYPE; TRANSPORTER; ASSOCIATION; RESISTANCE; WARFARIN;
D O I
10.23812/j.biol.regul.homeost.agents.20243803.144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pharmacogenomics (PGx), a rapidly evolving field at the intersection of pharmacology and genomics, has the potential to revolutionize medical practice by investigating how an individual's genetic makeup influences their response to drugs. By optimizing drug selection, dosage, and treatment strategies based on an individual's genetic profile, pharmacogenomics aims to improve therapeutic outcomes, minimize adverse reactions, and enhance healthcare efficiency. Recent advancements in high-throughput genotyping technologies and the availability of genomic data have paved the way for personalized and targeted therapies. This review highlights pharmacogenomics's fundamental principles, applications, and challenges, emphasizing its potential to transform clinical practice and patient care. The field has made significant progress in understanding the impact of genetic variants on drug response, ranging from monogenic to complex polygenic variants. However, the implementation of pharmacogenomics in public health institutions remains limited. With continuous advancements and increasing integration of genomics into medicine, pharmacogenomics is poised to play a crucial role in precision medicine, improving drug efficacy, minimizing toxicity, and driving advancements in drug discovery and development.
引用
收藏
页码:1809 / 1829
页数:21
相关论文
共 50 条
  • [21] RNA Interference, RSV, and Lung Transplantation A Promising Future for siRNA Therapeutics
    Astor, Todd L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (04) : 427 - 428
  • [22] Acute myeloid leukemia: advancing clinical trials and promising therapeutics
    Daver, Naval
    Cortes, Jorge
    Kantarjian, Hagop
    Ravandi, Farhad
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (05) : 433 - 445
  • [23] Improving early clinical trial phase identification of promising therapeutics
    Kent, Thomas A.
    Shah, Shreyansh D.
    Mandava, Pitchaiah
    NEUROLOGY, 2015, 85 (03) : 274 - 283
  • [24] Clinical Evaluation of Digital Therapeutics: Present and Future
    Huh, Ki Young
    Oh, Jaeseong
    Lee, SeungHwan
    Yu, Kyung-Sang
    HEALTHCARE INFORMATICS RESEARCH, 2022, 28 (03) : 188 - 197
  • [25] Natural Cyclic Peptides as Clinical and Future Therapeutics
    Bera, Smritilekha
    Mondal, Dhananjoy
    CURRENT ORGANIC CHEMISTRY, 2019, 23 (01) : 38 - 75
  • [26] Clinical pharmacology and therapeutics - Past, present and future
    Reid, JL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (01) : 101 - 103
  • [27] Clinical Pharmacology & Therapeutics: Past, Present, and Future
    Waldman, S. A.
    Terzic, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (03) : 300 - 303
  • [28] Clinical use of pharmacogenomics in Psychiatry: The future has not yet arrived
    Baune, B. T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2022, 58 : 4 - 6
  • [29] Prenatal pharmacogenomics: a promising area for research
    Dorfman, E. H.
    Cheng, E. Y.
    Hebert, M. F.
    Thummel, K. E.
    Burke, W.
    PHARMACOGENOMICS JOURNAL, 2016, 16 (04): : 303 - 304
  • [30] Prenatal pharmacogenomics: a promising area for research
    E H Dorfman
    E Y Cheng
    M F Hebert
    K E Thummel
    W Burke
    The Pharmacogenomics Journal, 2016, 16 : 303 - 304